schliessen

Filtern

 

Bibliotheken

Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies

•The benefit of G-CSF during induction in patients with non-M3 AML is less clear.•G-CSF administration accelerated neutrophil recovery without affecting survival.•Preemptive G-CSF administration reduced the duration of febrile neutropenia.•Preemptive G-CSF administration modestly improved treatment-... Full description

Journal Title: Leukemia Research June 2017, Vol.57, pp.1-8
Main Author: Kang, Ka-Won
Other Authors: Kim, Dae Sik , Lee, Se Ryeon , Sung, Hwa Jung , Kim, Seok Jin , Choi, Chul Won , Kim, Byung Soo , Park, Yong
Format: Electronic Article Electronic Article
Language: English
Subjects:
Aml
ANC
Cci
Ci
CR
Os
Rfs
Trm
ID: ISSN: 0145-2126 ; E-ISSN: 1873-5835 ; DOI: 10.1016/j.leukres.2017.02.003
Link: http://dx.doi.org/10.1016/j.leukres.2017.02.003
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_leukres_2017_02_003
title: Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies
format: Article
creator:
  • Kang, Ka-Won
  • Kim, Dae Sik
  • Lee, Se Ryeon
  • Sung, Hwa Jung
  • Kim, Seok Jin
  • Choi, Chul Won
  • Kim, Byung Soo
  • Park, Yong
subjects:
  • Acute Myelogenous Leukemia
  • Granulocyte Colony-Stimulating Factor
  • Neutropenia
  • Treatment-Related Mortality
  • Aml
  • ANC
  • Cci
  • Ci
  • Cifn
  • CR
  • G-Csf
  • Nccn
  • Os
  • Rfs
  • Trm
  • Acute Myelogenous Leukemia
  • Granulocyte Colony-Stimulating Factor
  • Neutropenia
  • Treatment-Related Mortality
  • Medicine
ispartof: Leukemia Research, June 2017, Vol.57, pp.1-8
description: •The benefit of G-CSF during induction in patients with non-M3 AML is less clear.•G-CSF administration accelerated neutrophil recovery without affecting survival.•Preemptive G-CSF administration reduced the duration of febrile neutropenia.•Preemptive G-CSF administration modestly improved treatment-related mortality. We analyzed the effects of granulocyte colony-stimulating factor (G-CSF) on outcomes in 315 anthracycline-based induction chemotherapy-treated patients with non-M3 acute myelogenous leukemia (AML). Patients were classified as follows: no G-CSF administration during induction (no G-CSF group; 112 patients); administration immediately upon neutropenia onset (absolute neutrophil counts (ANC)1000/μL), but before febrile neutropenia (preemptive group; 74 patients); and administration following febrile neutropenia development (therapeutic group; 129 patients). G-CSF users had a shorter time to ANC recovery than the no G-CSF group (p0.001). The...
language: eng
source:
identifier: ISSN: 0145-2126 ; E-ISSN: 1873-5835 ; DOI: 10.1016/j.leukres.2017.02.003
fulltext: fulltext
issn:
  • 0145-2126
  • 01452126
  • 1873-5835
  • 18735835
url: Link


@attributes
ID1740358094
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_leukres_2017_02_003
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_leukres_2017_02_003
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94CK
104G.
117-5
128P~
139JM
14AABNK
15AAEDT
16AAKOC
17AAOAW
18AAQFI
19ABBQC
20ABGSF
21ABMZM
22ABYKQ
23ACDAQ
24ACIUM
25ACRLP
26ADALY
27ADUVX
28AEHWI
29AEKER
30AEVXI
31AFKWA
32AFTJW
33AFXIZ
34AGHFR
35AGRDE
36AGUBO
37AGYEJ
38AHHHB
39AIKHN
40AITUG
41AJBFU
42AJOXV
43AJRQY
44AJUYK
45AMFUW
46ANZVX
47BLXMC
48BNPGV
49DOVZS
50EO8
51EO9
52EP2
53EP3
54FDB
55FGOYB
56FIRID
57FNPLU
58G-Q
59GBLVA
60HED
61HMK
62HMO
63J1W
64KOM
65LCYCR
66OAUVE
67OC~
68OO-
69P-8
70P-9
71PC.
72Q38
73R2-
74RPZ
75SAE
76SCC
77SDF
78SDG
79SEL
80SES
81SEW
82SSH
83SSU
84SSZ
85T5K
86Z5R
87~G-
pqid1872576868
galeid498029454
display
typearticle
titleEffect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies
creatorKang, Ka-Won ; Kim, Dae Sik ; Lee, Se Ryeon ; Sung, Hwa Jung ; Kim, Seok Jin ; Choi, Chul Won ; Kim, Byung Soo ; Park, Yong
ispartofLeukemia Research, June 2017, Vol.57, pp.1-8
identifier
subjectAcute Myelogenous Leukemia ; Granulocyte Colony-Stimulating Factor ; Neutropenia ; Treatment-Related Mortality ; Aml ; ANC ; Cci ; Ci ; Cifn ; CR ; G-Csf ; Nccn ; Os ; Rfs ; Trm ; Acute Myelogenous Leukemia ; Granulocyte Colony-Stimulating Factor ; Neutropenia ; Treatment-Related Mortality ; Medicine
description•The benefit of G-CSF during induction in patients with non-M3 AML is less clear.•G-CSF administration accelerated neutrophil recovery without affecting survival.•Preemptive G-CSF administration reduced the duration of febrile neutropenia.•Preemptive G-CSF administration modestly improved treatment-related mortality. We analyzed the effects of granulocyte colony-stimulating factor (G-CSF) on outcomes in 315 anthracycline-based induction chemotherapy-treated patients with non-M3 acute myelogenous leukemia (AML). Patients were classified as follows: no G-CSF administration during induction (no G-CSF group; 112 patients); administration immediately upon neutropenia onset (absolute neutrophil counts (ANC)1000/μL), but before febrile neutropenia (preemptive group; 74 patients); and administration following febrile neutropenia development (therapeutic group; 129 patients). G-CSF users had a shorter time to ANC recovery than the no G-CSF group (p0.001). The...
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://dx.doi.org/10.1016/j.leukres.2017.02.003$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Kang, Ka-Won
1Kim, Dae Sik
2Lee, Se Ryeon
3Sung, Hwa Jung
4Kim, Seok Jin
5Choi, Chul Won
6Kim, Byung Soo
7Park, Yong
titleEffect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies
description

•The benefit of G-CSF during induction in patients with non-M3 AML is less clear.•G-CSF administration accelerated neutrophil recovery without affecting survival.•Preemptive G-CSF administration reduced the duration of febrile neutropenia.•Preemptive G-CSF administration modestly improved treatment-related mortality.

We analyzed the effects of granulocyte colony-stimulating factor (G-CSF) on outcomes in 315 anthracycline-based induction chemotherapy-treated patients with non-M3 acute myelogenous leukemia (AML). Patients were classified as follows: no G-CSF administration during induction (no G-CSF group; 112 patients); administration immediately upon neutropenia onset (absolute neutrophil counts (ANC)<1000/μL), but before febrile neutropenia (preemptive group; 74 patients); and administration following febrile neutropenia development (therapeutic group; 129 patients). G-CSF users had a shorter time to ANC recovery than the no G-CSF group (p<0.001). The...

subject
0Acute Myelogenous Leukemia
1Granulocyte Colony-Stimulating Factor
2Neutropenia
3Treatment-Related Mortality
4Aml
5ANC
6Cci
7Ci
8Cifn
9CR
10G-Csf
11Nccn
12Os
13Rfs
14Trm
15Medicine
general
0English
1Elsevier Ltd
210.1016/j.leukres.2017.02.003
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_leukres_2017_02_003
issn
00145-2126
101452126
21873-5835
318735835
rsrctypearticle
creationdate2017
addtitleLeukemia Research
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94CK
104G.
117-5
128P~
139JM
14AABNK
15AAEDT
16AAKOC
17AAOAW
18AAQFI
19ABBQC
20ABGSF
21ABMZM
22ABYKQ
23ACDAQ
24ACIUM
25ACRLP
26ADALY
27ADUVX
28AEHWI
29AEKER
30AEVXI
31AFKWA
32AFTJW
33AFXIZ
34AGHFR
35AGRDE
36AGUBO
37AGYEJ
38AHHHB
39AIKHN
40AITUG
41AJBFU
42AJOXV
43AJRQY
44AJUYK
45AMFUW
46ANZVX
47BLXMC
48BNPGV
49DOVZS
50EO8
51EO9
52EP2
53EP3
54FDB
55FGOYB
56FIRID
57FNPLU
58G-Q
59GBLVA
60HED
61HMK
62HMO
63J1W
64KOM
65LCYCR
66OAUVE
67OC~
68OO-
69P-8
70P-9
71PC.
72Q38
73R2-
74RPZ
75SAE
76SCC
77SDF
78SDG
79SEL
80SES
81SEW
82SSH
83SSU
84SSZ
85T5K
86Z5R
87~G-
startdate20170601
enddate20170631
lsr40Leukemia Research, June 2017, Vol.57, pp.1-8
doi10.1016/j.leukres.2017.02.003
citationpf 1 pt 8 vol 57
lsr30VSR-Enriched:[galeid, pqid]
sort
titleEffect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies
authorKang, Ka-Won ; Kim, Dae Sik ; Lee, Se Ryeon ; Sung, Hwa Jung ; Kim, Seok Jin ; Choi, Chul Won ; Kim, Byung Soo ; Park, Yong
creationdate20170600
lso0120170600
facets
frbrgroupid8325523813319900751
frbrtype5
newrecords20190904
languageeng
topic
0Acute Myelogenous Leukemia
1Granulocyte Colony-Stimulating Factor
2Neutropenia
3Treatment-Related Mortality
4Aml
5ANC
6Cci
7Ci
8Cifn
9CR
10G-Csf
11Nccn
12Os
13Rfs
14Trm
15Medicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Kang, Ka-Won
1Kim, Dae Sik
2Lee, Se Ryeon
3Sung, Hwa Jung
4Kim, Seok Jin
5Choi, Chul Won
6Kim, Byung Soo
7Park, Yong
jtitleLeukemia Research
creationdate2017
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Kang
1Kim
2Lee
3Sung
4Choi
5Park
aufirst
0Ka-Won
1Dae Sik
2Se Ryeon
3Hwa Jung
4Seok Jin
5Chul Won
6Byung Soo
7Yong
auinitK
auinit1K
au
0Kang, Ka-Won
1Kim, Dae Sik
2Lee, Se Ryeon
3Sung, Hwa Jung
4Kim, Seok Jin
5Choi, Chul Won
6Kim, Byung Soo
7Park, Yong
atitleEffect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies
jtitleLeukemia Research
risdate201706
volume57
spage1
epage8
pages1-8
issn0145-2126
eissn1873-5835
formatjournal
genrearticle
ristypeJOUR
abstract

•The benefit of G-CSF during induction in patients with non-M3 AML is less clear.•G-CSF administration accelerated neutrophil recovery without affecting survival.•Preemptive G-CSF administration reduced the duration of febrile neutropenia.•Preemptive G-CSF administration modestly improved treatment-related mortality.

We analyzed the effects of granulocyte colony-stimulating factor (G-CSF) on outcomes in 315 anthracycline-based induction chemotherapy-treated patients with non-M3 acute myelogenous leukemia (AML). Patients were classified as follows: no G-CSF administration during induction (no G-CSF group; 112 patients); administration immediately upon neutropenia onset (absolute neutrophil counts (ANC)<1000/μL), but before febrile neutropenia (preemptive group; 74 patients); and administration following febrile neutropenia development (therapeutic group; 129 patients). G-CSF users had a shorter time to ANC recovery than the no G-CSF group (p<0.001). The...

pubElsevier Ltd
doi10.1016/j.leukres.2017.02.003
lad01Leukemia Research
date2017-06